Incremental yield of including determine-TB LAM assay in diagnostic algorithms for hospitalized and ambulatory HIV-positive patients in Kenya

PLoS ONE

Volumn 12, Issue 1, 2017, Pages

  Huerga, Helena ^a   Ferlazzo, Gabriella ^b   Bevilacqua, Paolo ^a   Kirubi, Beatrice ^c   Ardizzoni, Elisa ^b,c   Wanjala, Stephen ^b   Sitienei, Joseph ^d   Bonnet, Maryline ^a,e  

^a EPICENTRE   (France)

^b MÉDECINS SANS FRONTIÈRES   (Switzerland)

^c INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^d MINISTRY OF HEALTH   (Kenya)

^e INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BACTERIUM CULTURE; BODY MASS; CD4 LYMPHOCYTE COUNT; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DISEASE SEVERITY; FEMALE; HOSPITAL PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KENYA; LAM ASSAY; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MICROSCOPY; MORTALITY; OBSERVATIONAL STUDY; PROSPECTIVE STUDY; SPUTUM ANALYSIS; SPUTUM SMEAR; THORAX RADIOGRAPHY; TUBERCULOSIS RAPID TEST; ALGORITHM; COMPLICATION; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; POINT OF CARE SYSTEM; TUBERCULOSIS, PULMONARY;

LIPOARABINOMANNAN; LIPOPOLYSACCHARIDE;

ADULT; ALGORITHMS; FEMALE; HIV INFECTIONS; HUMANS; KENYA; LIPOPOLYSACCHARIDES; MALE; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; POINT-OF-CARE SYSTEMS; TUBERCULOSIS, PULMONARY;

EID: 85010987156     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0170976     Document Type: Article

References (30)

1. World Health Organisation. Policy statement: automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF system. Geneva; 2011.
2. Lawn SD, Mwaba P, Bates M, Piatek A, Alexander H, Marais BJ, et al. Advances in tuberculosis diagnostics: The Xpert MTB/RIF assay and future prospects for a point-of-care test. The Lancet Infectious Diseases. 2013. pp. 349-361. doi: 10.1016/S1473-3099(13)70008-2 PMID: 23531388
3. Davis JL, Worodria W, Kisembo H, Metcalfe JZ, Cattamanchi A, Kawooya M, et al. Clinical and radiographic factors do not accurately diagnose smear-negative tuberculosis in HIV-infected inpatients in Uganda: a cross-sectional study. PLoS One. 2010; 5: e9859. doi: 10.1371/journal.pone.0009859 PMID: 20361038
4. van Cleeff MRA, Kivihya-Ndugga LE, Meme H, Odhiambo JA, Klatser PR. The role and performance of chest X-ray for the diagnosis of tuberculosis: a cost-effectiveness analysis in Nairobi, Kenya. BMC Infect Dis. 2005; 5: 111. doi: 10.1186/1471-2334-5-111 PMID: 16343340
5. Lawn SD, Gupta-Wright A. Detection of lipoarabinomannan (LAM) in urine is indicative of disseminated TB with renal involvement in patients living with hiv and advanced immunodeficiency: Evidence and implications. Transactions of the Royal Society of Tropical Medicine and Hygiene. 2015. pp. 180-185.
6. Peter JG, Theron G, Dheda K. Can point-of-care urine LAM strip testing for tuberculosis add value to clinical decision making in hospitalised HIV-infected persons? PLoS One. 2013; 8: e54875. doi: 10.1371/journal.pone.0054875 PMID: 23390504
7. Lawn SD, Dheda K, Kerkhoff AD, Peter JG, Dorman S, Boehme CC, et al. Determine TB-LAM lateral flow urine antigen assay for HIV-associated tuberculosis: recommendations on the design and reporting of clinical studies. BMC Infect Dis. 2013; 13: 407. doi: 10.1186/1471-2334-13-407 PMID: 24004840
8. Shah M, Hanrahan C, Wang ZY, Dendukuri N, Lawn SD, Denkinger CM, et al. Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in HIV-positive adults. In: Shah M, editor. Cochrane Database of Systematic Reviews. Chichester, UK: John Wiley & Sons, Ltd; 2016.
9. World Health Organisation. The use of lateral flow urine lipoarabinomannan assay (LF-LAM) for the diagnosis and screening of active tuberculosis in people living with HIV. Policy guidance. [Internet]. Geneva: World Health Organisation; 2015. p. 74. http://apps.who.int/iris/bitstream/10665/193633/1/9789241509633-eng.pdf?ua=1&ua=1
10. World Health Organisation. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Geneva: World Health Organisation; 2016. p. 480.
11. National Tuberculosis Leprosy and Lung Diseases Program. Annual Report 2014. Nairobi; 2014.
12. Ministry of Health. Kenya HIV estimates. Nairobi; 2014.
13. Huerga H, Spillane H, Guerrero W, Odongo A, Varaine F. Impact of introducing human immunodeficiency virus testing, treatment and care in a tuberculosis clinic in rural Kenya. Int J Tuberc Lung Dis. 2010; 14: 611-5. Available: http://www.ncbi.nlm.nih.gov/pubmed/20392355 PMID: 20392355
14. Mejia GI, Castrillon L, Trujillo H, Robledo J a. Microcolony detection in 7H11 thin layer culture is an alternative for rapid diagnosis of Mycobacterium tuberculosis infection. Int J Tuberc Lung Dis. 1999; 3: 138-42. Available: http://www.ncbi.nlm.nih.gov/pubmed/10091879 PMID: 10091879
15. Lawn SD. Point-of-care detection of lipoarabinomannan (LAM) in urine for diagnosis of HIV-associated tuberculosis: a state of the art review. BMC Infect Dis. BioMed Central Ltd; 2012; 12: 103.
16. Bjerrum S, Kenu E, Lartey M, Newman MJ, Addo KK, Andersen AB, et al. Diagnostic accuracy of the rapid urine lipoarabinomannan test for pulmonary tuberculosis among HIV-infected adults in Ghanafindings from the DETECT HIV-TB study. BMC Infect Dis. 2015; 15: 407. doi: 10.1186/s12879-015-1151-1 PMID: 26427365
17. Shah M, Ssengooba W, Armstrong D, Nakiyingi L, Holshouser M, Ellner JJ, et al. Comparative performance of urinary lipoarabinomannan assays and Xpert MTB/RIF in HIV-infected individuals. AIDS. 2014; 28: 1307-14. doi: 10.1097/QAD.0000000000000264 PMID: 24637544
18. Talbot E, Munseri P, Teixeira P, Matee M, Bakari M, Lahey T, et al. Test characteristics of urinary lipoarabinomannan and predictors of mortality among hospitalized HIV-infected tuberculosis suspects in Tanzania. PLoS One. 2012; 7: e32876. doi: 10.1371/journal.pone.0032876 PMID: 22412939
19. Drain PK, Losina E, Coleman SM, Giddy J, Ross D, Katz JN, et al. Value of urine lipoarabinomannan grade and second test for optimizing clinic-based screening for HIV-associated pulmonary tuberculosis. J Acquir Immune Defic Syndr. 2015; 68: 274-80. doi: 10.1097/QAI.0000000000000436 PMID: 25415288
20. Nakiyingi L, Moodley VM, Manabe YC, Nicol MP, Holshouser M, Armstrong DT, et al. Diagnostic accuracy of a rapid urine lipoarabinomannan test for tuberculosis in HIV-infected adults. J Acquir Immune Defic Syndr. 2014
21. Peter JG, Zijenah LS, Chanda D, Clowes P, Lesosky M, Gina P, et al. Effect on mortality of point-ofcare, urine-based lipoarabinomannan testing to guide tuberculosis treatment initiation in HIV-positive hospital inpatients: a pragmatic, parallel-group, multicountry, open-label, randomised controlled trial. Lancet. 2016; 387: 1187-97. doi: 10.1016/S0140-6736(15)01092-2 PMID: 26970721
22. Kerkhoff AD, Wood R, Vogt M, Lawn SD. Prognostic value of a quantitative analysis of lipoarabinomannan in urine from patients with HIV-associated tuberculosis. PLoS One. 2014; 9: e103285. doi: 10.1371/journal.pone.0103285 PMID: 25075867
23. Manabe YC, Nonyane BAS, Nakiyingi L, Mbabazi O, Lubega G, Shah M, et al. Point-of-care lateral flow assays for tuberculosis and cryptococcal antigenuria predict death in HIV infected adults in Uganda. PLoS One. 2014; 9: e101459. doi: 10.1371/journal.pone.0101459 PMID: 25000489
24. Drain PK, Gounder L, Grobler A, Sahid F, Bassett I V, Moosa M-YS. Urine lipoarabinomannan to monitor antituberculosis therapy response and predict mortality in an HIV-endemic region: a prospective cohort study. BMJ Open. 2015; 5: e006833. doi: 10.1136/bmjopen-2014-006833 PMID: 25877271
25. Peter J, Theron G, Chanda D, Clowes P, Rachow A, Lesosky M, et al. Test characteristics and potential impact of the urine LAM lateral flow assay in HIV-infected outpatients under investigation for TB and able to self-expectorate sputum for diagnostic testing. BMC Infect Dis. 2015; 15: 262. doi: 10.1186/s12879-015-0967-z PMID: 26156025
26. Gupta-Wright A, Peters JA, Flach C, Lawn SD. Detection of lipoarabinomannan (LAM) in urine is an independent predictor of mortality risk in patients receiving treatment for HIV-associated tuberculosis in sub-Saharan Africa: a systematic review and meta-analysis. BMC Med. 2016; 14: 53. doi: 10.1186/s12916-016-0603-9 PMID: 27007773
27. Lawn SD, Kerkhoff AD, Vogt M, Ghebrekristos Y, Whitelaw A, Wood R. Characteristics and early outcomes of patients with Xpert MTB/RIF-negative pulmonary tuberculosis diagnosed during screening before antiretroviral therapy. Clin Infect Dis. 2012; 54: 1071-9. doi: 10.1093/cid/cir1039 PMID: 22318975
28. Nakiyingi L, Moodley VM, Manabe YC, Nicol MP, Holshouser M, Armstrong DT, et al. Diagnostic accuracy of a rapid urine lipoarabinomannan test for tuberculosis in HIV-infected adults. J Acquir Immune Defic Syndr. 2014; 66: 270-9. doi: 10.1097/QAI.0000000000000151 PMID: 24675585
29. Lawn SD, Kerkhoff AD, Nicol MP, Meintjes G. Underestimation of the True Specificity of the Urine Lipoarabinomannan Point-of-Care Diagnostic Assay for HIV-Associated Tuberculosis. J Acquir Immune Defic Syndr. 2015; 69: e144-6. doi: 10.1097/QAI.0000000000000672 PMID: 25961395
30. Gupta RK, Lucas SB, Fielding KL, Lawn SD. Prevalence of tuberculosis in post-mortem studies of HIVinfected adults and children in resource-limited settings: a systematic review and meta-analysis. AIDS. 2015; 29: 1987-2002. doi: 10.1097/QAD.0000000000000802 PMID: 26266773